PT Indofarma Tbk

As of June 30, 2026, PT Indofarma Tbk has 3.10B shares outstanding.

These figures are as of June 30, 2026. The EV/Sales ratio of 4.39 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. PT Indofarma Tbk trades at an EV/FCF ratio of 11.39, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2026, PT Indofarma Tbk maintains a current ratio of 0.15, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -97.67, indicating conservative leverage, while an interest coverage ratio of -3.07 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -12.62, reflecting losses generated across the asset base. Inventory turnover of 2.79 indicates how many times PT Indofarma Tbk sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PT Indofarma Tbk posted a gross margin of -0.82, reflecting its pricing power and cost economics. The operating margin of -105.65 and net profit margin of -41.31 provide insight into operational efficiency.

As of June 30, 2026, PT Indofarma Tbk has an Altman Z-Score of -6.15, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.